Back to Search Start Over

The Multi-Targeting Ligand ST-2223 with Histamine H 3 Receptor and Dopamine D 2 /D 3 Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in Mice.

Authors :
Eissa, Nermin
Venkatachalam, Karthikkumar
Jayaprakash, Petrilla
Falkenstein, Markus
Dubiel, Mariam
Frank, Annika
Reiner-Link, David
Stark, Holger
Sadek, Bassem
Yui, Kunio
Source :
International Journal of Molecular Sciences; Feb2021, Vol. 22 Issue 4, p1947-1947, 1p
Publication Year :
2021

Abstract

Autism spectrum disorder (ASD) is a complex heterogeneous neurodevelopmental disorder characterized by social and communicative impairments, as well as repetitive and restricted behaviors (RRBs). With the limited effectiveness of current pharmacotherapies in treating repetitive behaviors, the present study determined the effects of acute systemic treatment of the novel multi-targeting ligand ST-2223, with incorporated histamine H<subscript>3</subscript> receptor (H<subscript>3</subscript>R) and dopamine D<subscript>2</subscript>/D<subscript>3</subscript> receptor affinity properties, on ASD-related RRBs in a male Black and Tan BRachyury (BTBR) mouse model of ASD. ST-2223 (2.5, 5, and 10 mg/kg, i.p.) significantly mitigated the increase in marble burying and self-grooming, and improved reduced spontaneous alternation in BTBR mice (all p < 0.05). Similarly, reference drugs memantine (MEM, 5 mg/kg, i.p.) and aripiprazole (ARP, 1 mg/kg, i.p.), reversed abnormally high levels of several RRBs in BTBR (p < 0.05). Moreover, ST-2223 palliated the disturbed anxiety levels observed in an open field test (all p < 0.05), but did not restore the hyperactivity parameters, whereas MEM failed to restore mouse anxiety and hyperactivity. In addition, ST-2223 (5 mg/kg, i.p.) mitigated oxidative stress status by decreasing the elevated levels of malondialdehyde (MDA), and increasing the levels of decreased glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) in different brain parts of treated BTBR mice (all p < 0.05). These preliminary in vivo findings demonstrate the ameliorative effects of ST-2223 on RRBs in a mouse model of ASD, suggesting its pharmacological prospective to rescue core ASD-related behaviors. Further confirmatory investigations on its effects on various brain neurotransmitters, e.g., dopamine and histamine, in different brain regions are still warranted to corroborate and expand these initial data. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
22
Issue :
4
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
149018672
Full Text :
https://doi.org/10.3390/ijms22041947